Repligen Corp (NASDAQ:RGEN) released on Tuesday third-quarter adjusted EPS of 43 cents, up from 23 cents a year ago, beating the consensus of 33 cents. The bioprocessing technology reported sales of ...

Repligen's price target has recently seen a modest increase, with fair value estimates rising from $179.78 to $184.76. This reflects cautious optimism from analysts. The upward revision is rooted in ...

Repligen (RGEN) released its third quarter results, revealing year-over-year growth in both revenue and net income. The company shifted from last year’s net loss into positive territory and also ...

Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) reported Q2 CY2025 results , with sales up 14.8% year on year to $182.4 million. The company’s full-year revenue guidance of $725 ...

For the three-month stretch ending in March, Repligen Corporation turned record-breaking revenue of $206.4 million into operating earnings of $0.92 per share. Organic revenue was up 44% year over year ...

Sands Capital, an investment management company, released its “Sands Capital Global Growth Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. Global Growth adopts a ...

A month has gone by since the last earnings report for Repligen (RGEN). Shares have lost about 11.4% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading up ...

SVB Securities analyst Puneet Souda maintained a Buy rating on Repligen (RGEN - Research Report) on November 1 and set a price target of $230.00. The companys shares closed yesterday at $173.46.